SBI Securities Co. Ltd. Acquires 1,803 Shares of TransMedics Group, Inc. $TMDX

SBI Securities Co. Ltd. raised its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 48.9% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,487 shares of the company’s stock after purchasing an additional 1,803 shares during the period. SBI Securities Co. Ltd.’s holdings in TransMedics Group were worth $735,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of TMDX. Verus Capital Partners LLC bought a new position in shares of TransMedics Group during the second quarter worth about $222,000. 49 Wealth Management LLC acquired a new stake in TransMedics Group during the 2nd quarter valued at approximately $235,000. Americana Partners LLC bought a new position in TransMedics Group during the 2nd quarter worth approximately $201,000. Profund Advisors LLC bought a new stake in shares of TransMedics Group in the 2nd quarter valued at $224,000. Finally, Lisanti Capital Growth LLC increased its position in shares of TransMedics Group by 21.7% during the second quarter. Lisanti Capital Growth LLC now owns 35,130 shares of the company’s stock worth $4,708,000 after buying an additional 6,260 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Trading Down 3.0%

TMDX opened at $115.55 on Friday. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $145.50. The firm has a market capitalization of $3.95 billion, a PE ratio of 46.78 and a beta of 2.05. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13. The company’s 50-day moving average is $118.60 and its 200 day moving average is $119.42.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The firm had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. During the same period in the previous year, the company posted $0.12 EPS. The company’s revenue for the quarter was up 32.2% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on TMDX shares. Jefferies Financial Group began coverage on shares of TransMedics Group in a report on Monday, October 13th. They issued a “buy” rating and a $145.00 target price on the stock. Needham & Company LLC restated a “buy” rating on shares of TransMedics Group in a research report on Thursday, October 30th. Zacks Research downgraded TransMedics Group from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Morgan Stanley increased their price target on TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Finally, Canaccord Genuity Group lifted their price objective on shares of TransMedics Group from $142.00 to $147.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $130.73.

Insider Buying and Selling

In other TransMedics Group news, Director Edward M. Basile sold 4,142 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $130.45, for a total transaction of $540,323.90. Following the transaction, the director directly owned 2,866 shares in the company, valued at approximately $373,869.70. This trade represents a 59.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 7.00% of the company’s stock.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.